Bitte benutzen Sie diese Kennung, um auf die Ressource zu verweisen:
http://doi.org/10.25358/openscience-6284
Autoren: | Wölfinger, Pascal Epp, Katharina Schaefer, Lukas Kriege, Diana Theobald, Matthias Bopp, Tobias Wagner-Drouet, Eva-Maria |
Titel: | CD52-negative T cells predict acute graft-versus-host disease after an alemtuzumab-based conditioning regimen |
Online-Publikationsdatum: | 16-Aug-2021 |
Erscheinungsdatum: | 2020 |
Sprache des Dokuments: | Englisch |
Zusammenfassung/Abstract: | Allogeneic haematopoietic stem cell transplantation (HSCT) after a reduced-intensity conditioning (RIC) regimen with fludarabine, melphalan and alemtuzmab is an effective therapy for haematological malignancies. Alemtuzumab, a monoclonal antibody against CD52, a glycosylphosphatidylinositol-anchor-bound surface protein on lymphocytes, depletes T cells to prevent graft-versus-host disease (GVHD). Despite this, acute and chronic GVHD (a/cGVHD) remain life-threatening complications after HSCT. The aim of the present study was to identify parameters to predict GVHD. In 69 patients after HSCT, T-cell subsets were functionally analysed. Reconstitution of CD52neg T cells and CD52neg regulatory T cells (Tregs) correlated with onset, severity and clinical course of aGVHD. Patients with aGVHD showed significantly lower levels of CD52pos T cells compared to patients with cGVHD or without GVHD (P < 0·001). Analysis of T-cell reconstitution revealed a percentage of <40% of CD52posCD4pos T cells or CD52pos Tregs at day +50 as a risk factor for the development of aGVHD. In contrast, CD52neg Tregs showed significant decreased levels of glycoprotein A repetitions predominant (GARP; P < 0·001), glucocorticoid-induced TNFR-related protein (GITR; P < 0·001), chemokine receptor (CXCR3; P = 0·023), C-C chemokine receptor type 5 (CCR5; P = 0·004), but increased levels of immunoglobulin-like transcript 3 (ILT3; P = 0·001), as well as a reduced suppressive capacity. We conclude that reconstitution of CD52neg T cells and CD52neg Tregs is a risk factor for development of aGVHD. |
DDC-Sachgruppe: | 610 Medizin 610 Medical sciences |
Veröffentlichende Institution: | Johannes Gutenberg-Universität Mainz |
Organisationseinheit: | FB 04 Medizin |
Veröffentlichungsort: | Mainz |
ROR: | https://ror.org/023b0x485 |
DOI: | http://doi.org/10.25358/openscience-6284 |
Version: | Published version |
Publikationstyp: | Zeitschriftenaufsatz |
Nutzungsrechte: | CC BY-NC |
Informationen zu den Nutzungsrechten: | https://creativecommons.org/licenses/by-nc/4.0/ |
Zeitschrift: | British journal of haematology 191 2 |
Seitenzahl oder Artikelnummer: | 253 262 |
Verlag: | Wiley-Blackwell |
Verlagsort: | Oxford u.a. |
Erscheinungsdatum: | 2020 |
ISSN: | 1365-2141 |
URL der Originalveröffentlichung: | https://doi.org/10.1111/bjh.16706 |
DOI der Originalveröffentlichung: | 10.1111/bjh.16706 |
Enthalten in den Sammlungen: | JGU-Publikationen |
Dateien zu dieser Ressource:
Datei | Beschreibung | Größe | Format | ||
---|---|---|---|---|---|
woelfinger_pascal-cd52-negative_-20210816104941103.pdf | 1.22 MB | Adobe PDF | Öffnen/Anzeigen |